Quanyin Hu

About

Prof. Hu received his Ph.D. degree in Biomedical Engineering from the University of North Carolina at Chapel Hill and North Carolina State University under the supervision of Prof. Zhen Gu in 2018. From 2018-2020, he was a postdoc associate in the laboratory of Prof. Robert Langer in Koch Institute for Integrative Cancer Research at MIT. Prof. Hu joined UW-Madison in 2020 as an assistant professor and was promoted to the Associate Professor and Joseph R. and Bonna A. Robinson Distinguished Chair in 2025 in the Pharmaceutical Sciences Division at the School of Pharmacy.

Research topics

• Medicine
• Immunology
• Cancer research
• Chemistry
• Materials science
• Biology
• Nanotechnology
• Engineering
• Pharmacology
• Internal medicine

Selected publications

• Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets

  Nature Biomedical Engineering · 2021 · 364 citations

  1st authorCorresponding
  DOI

• Chemically and Biologically Engineered Bacteria‐Based Delivery Systems for Emerging Diagnosis and Advanced Therapy

  Advanced Materials · 2021 · 236 citations

  Senior authorCorresponding

  Bacteria are one of the main groups of organisms, which dynamically and closely participate in human health and disease development. With the integration of chemical biotechnology, bacteria have been utilized as an emerging delivery system for various biomedical applications. Given the unique features of bacteria such as their intrinsic biocompatibility and motility, bacteria-based delivery systems have drawn wide interest in the diagnosis and treatment of various diseases, including cancer, inf…

  DOI

• Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment

  Nature Communications · 2022 · 185 citations

  Senior authorCorresponding

  Immunosuppressive cells residing in the tumor microenvironment, especially tumor associated macrophages (TAMs), hinder the infiltration and activation of T cells, limiting the anti-cancer outcomes of immune checkpoint blockade. Here, we report a biocompatible alginate-based hydrogel loaded with Pexidartinib (PLX)-encapsulated nanoparticles that gradually release PLX at the tumor site to block colony-stimulating factor 1 receptors (CSF1R) for depleting TAMs. The controlled TAM depletion creates a…

  DOI

• Cell‐Based Delivery Systems: Emerging Carriers for Immunotherapy

  Advanced Functional Materials · 2021 · 130 citations

  Senior authorCorresponding

  Abstract Immunotherapy is leading a paradigm shift in the treatment of various diseases, including tumors, auto‐immune diseases, and infectious diseases. However, the limited response rate and systemic side effects significantly impede the clinical applications of immunotherapy. As natural carriers for proteins and molecules, cells with low immunogenicity and toxicity have attracted considerable attention for biomedical applications and have achieved encouraging progress especially in immunother…

  DOI

• Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design

  Chemical Society Reviews · 2024-01-01 · 41 citations

  reviewSenior authorCorresponding

  applications of TPD strategies by reshaping their pharmacokinetics and pharmacodynamic profiles. These proteolysis-targeting drug delivery systems (ProDDSs) exhibit superior delivery performance, enhanced targetability, and reduced off-tissue side effects. In this review, we will survey the latest progress in TPD-inspired drug delivery systems, highlight the importance of introducing delivery ideas or technologies to the development of protein degraders, outline design principles of protein degr…

  PublisherDOI

Frequent coauthors

• Zhen Gu

  Zhejiang University

  321 shared

• Jinqiang Wang

  Jinhua Academy of Agricultural Sciences

  122 shared

• Qian Chen

  Fifth Hospital of Shijiazhuang

  118 shared

• Wujin Sun

  Virginia Tech

  106 shared

• Chao Wang

  104 shared

• Guojun Chen

  89 shared

• Di Wen

  Hebei Medical University

  77 shared

• Yixin Wang

  University of Wisconsin Carbone Cancer Center

  58 shared

Labs

• Hu CIPT LabPI

Similar researchers at University of Wisconsin-Madison

• Weibo Caih-113
• Jeffrey Johnsonh-109
• Glen Kwonh-66